Description
Key facts
Cell type:A-431,
Species or organism:Human,
Tissue:Skin,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 26 bp deletion Frameshift: 100%,
Disease:Epidermoid Carcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ACSL4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FACL4 also known as ACSL4 is a member of the long-chain acyl-CoA synthetase (ACSL) family. This enzyme catalyzes the activation of long-chain fatty acids by forming a thioester bond with coenzyme A. FACL4 plays a critical role in lipid metabolism. The molecular weight of FACL4 is approximately 80 kDa. This protein is expressed in various tissues with a higher presence in the brain and testis reflecting its important function in lipid-related processes in these areas.
Biological function summary
FACL4 contributes significantly to lipid metabolism and is involved in the synthesis of complex lipids. It facilitates the integration of long-chain fatty acids into phospholipids and triglycerides. FACL4 often functions as part of larger lipid synthesis and modification complexes working closely with other enzymes to maintain membrane integrity and signal transduction. Its activity influences cellular responses to changes in lipid availability and metabolic demands.
Pathways
FACL4 functions within the arachidonic acid metabolism and glycerophospholipid metabolic pathways. In these pathways other proteins such as COX and LOX interact with FACL4 to regulate inflammatory responses and membrane lipid composition. The enzyme's role in these pathways highlights its contribution to managing the balance between pro-inflammatory and anti-inflammatory metabolites which are essential for cell signaling and homeostasis.
FACL4 is implicated in several neuropsychiatric conditions including X-linked adrenoleukodystrophy and breast cancer. In the context of these diseases FACL4 interacts with proteins like ALDP in adrenoleukodystrophy. Disrupted FACL4 activity can lead to abnormal lipid accumulation or impaired lipid signaling underlying the pathophysiology of these conditions. Understanding the role of FACL4 in these disorders highlights its potential as a therapeutic target for correcting lipid metabolism dysfunction.
